Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Research Article

Use of Sodium-Glucose Co-Transporter-2-Inhibitors (SGLT2-Is) and Risk of Lower Limb Amputation

Author(s): Nikki C.C. Werkman, Johannes T.H. Nielen, Joop P.W. van den Bergh , Niels Ejskjaer, Johan Røikjer, Nicolaas C. Schaper, Bernardette Rossi , Olaf Klungel, Peter Vestergaard, Frank de Vries* and Johanna H.M. Driessen

Volume 16 , Issue 1 , 2021

Published on: 05 August, 2020

Page: [62 - 72] Pages: 11

DOI: 10.2174/1574886315666200805103053

Price: $65

Abstract

Background: Treatment with sodium-glucose co-transporter-2-inhibitors (SGLT2-Is), such as canagliflozin, has been associated with an increased risk of lower limb amputations (LLAs) in type 2 diabetes mellitus (T2DM). However, conflicting results have been reported for different SGLT2-Is and the underlying mechanism is unclear.

Objective: To investigate the risk of LLA and diabetic foot ulcer with SGLT2-I use compared to other anti-diabetic drugs and to explore hypovolemia as a potential underlying mechanism.

Methods: A cohort study was conducted using data from the Clinical Practice Research Datalink GOLD (2013-2019). The study population (N=51,847) consisted of T2DM patients over 18 years of age with at least one prescription of a non-insulin anti-diabetic drug. Concomitant diuretic use and the presence of signs of hypovolemia were determined to assess the potential underlying mechanism. Cox proportional hazard models were used to estimate the hazard ratio (HR) for LLA in current SGLT2-I use versus current sulphonylurea (SU) use. Analyses were adjusted for lifestyle variables, comorbidities, and concomitant drug use.

Results: Current SGLT2-I use was not associated with an increased risk of LLA compared to current SU use (fully adjusted HR 0.70; 95% confidence interval 0.38-1.29). Concomitant use of diuretics and the presence of signs of hypovolemia were not associated with an increased risk of LLA.

Conclusion: Use of SGLT2-Is, with or without signs of hypovolemia, was not associated with an increased risk of LLA or DFU versus current SU use. Future studies powered to detect potential differences between individual SGLT2-Is are required to rule out a canagliflozin-specific effect.

Keywords: SGLT2 inhibitors, Type 2 diabetes mellitus, Amputation, Hypovolemia, Cohort study, CPRD.

Graphical Abstract
[1]
Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med 2014; 370(16): 1514-23.
[http://dx.doi.org/10.1056/NEJMoa1310799 ] [PMID: 24738668]
[2]
Costa RHR, Cardoso NA, Procópio RJ, Navarro TP, Dardik A, de Loiola Cisneros L. Diabetic foot ulcer carries high amputation and mortality rates, particularly in the presence of advanced age, peripheral artery disease and anemia. Diabetes Metab Syndr 2017; 11(Suppl. 2): S583-7.
[http://dx.doi.org/10.1016/j.dsx.2017.04.008 ] [PMID: 28465149]
[3]
Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol 2013; 1(2): 140-51.
[http://dx.doi.org/10.1016/S2213-8587(13)70050-0 ] [PMID: 24622320]
[4]
Li J, Gong Y, Li C, Lu Y, Liu Y, Shao Y. Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus: A meta-analysis. Medicine (Baltimore) 2017; 96(27)e7201
[http://dx.doi.org/10.1097/MD.0000000000007201 ] [PMID: 28682870]
[5]
Mearns ES, Sobieraj DM, White CM, et al. Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis. PLoS One 2015; 10(4)e0125879
[http://dx.doi.org/10.1371/journal.pone.0125879 ] [PMID: 25919293]
[6]
Dorsey-Treviño EG, González-González JG, Alvarez-Villalobos N, et al. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis. J Endocrinol Invest 2020; 43(3): 289-304.
[http://dx.doi.org/10.1007/s40618-019-01103-9 ] [PMID: 31489568]
[7]
Neal B, Perkovic V, Mahaffey KW, et al. CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017; 377(7): 644-57.
[http://dx.doi.org/10.1056/NEJMoa1611925 ] [PMID: 28605608]
[8]
Udell JA, Yuan Z, Rush T, Sicignano NM, Galitz M, Rosenthal N. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the easel population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World). Circulation 2018; 137(14): 1450-9.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.117.031227 ] [PMID: 29133607]
[9]
Chang HY, Singh S, Mansour O, Baksh S, Alexander GC. Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes. JAMA Intern Med 2018; 178(9): 1190-8.
[http://dx.doi.org/10.1001/jamainternmed.2018.3034 ] [PMID: 30105373]
[10]
Yang JY, Wang T, Pate V, et al. Sodium-glucose co-transporter-2 inhibitor use and risk of lower-extremity amputation: Evolving questions, evolving answers. Diabetes Obes Metab 2019; 21(5): 1223-36.
[http://dx.doi.org/10.1111/dom.13647 ] [PMID: 30697897]
[11]
Adimadhyam S, Lee TA, Calip GS, Smith Marsh DE, Layden BT, Schumock GT. Risk of amputations associated with SGLT2 inhibitors compared to DPP-4 inhibitors: A propensity-matched cohort study. Diabetes Obes Metab 2018; 20(12): 2792-9.
[http://dx.doi.org/10.1111/dom.13459 ] [PMID: 29971914]
[12]
Yuan Z, DeFalco FJ, Ryan PB, et al. Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: A retrospective cohort study. Diabetes Obes Metab 2018; 20(3): 582-9.
[http://dx.doi.org/10.1111/dom.13115 ] [PMID: 28898514]
[13]
Ryan PB, Buse JB, Schuemie MJ, et al. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D). Diabetes Obes Metab 2018; 20(11): 2585-97.
[http://dx.doi.org/10.1111/dom.13424 ] [PMID: 29938883]
[14]
Monteiro-Soares M, Ribeiro-Vaz I, Boyko EJ. Canagliflozin should be prescribed with caution to individuals with type 2 diabetes and high risk of amputation. Diabetologia 2019; 62(6): 900-4.
[http://dx.doi.org/10.1007/s00125-019-4861-x ] [PMID: 30941448]
[15]
Fadini GP, Avogaro A. SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System. Lancet Diabetes Endocrinol 2017; 5(9): 680-1.
[http://dx.doi.org/10.1016/S2213-8587(17)30257-7 ] [PMID: 28733172]
[16]
Potier L, Roussel R, Velho G, et al. Lower limb events in individuals with type 2 diabetes: evidence for an increased risk associated with diuretic use. Diabetologia 2019; 62(6): 939-47.
[http://dx.doi.org/10.1007/s00125-019-4835-z ] [PMID: 30809716]
[17]
Herrett E, Gallagher AM, Bhaskaran K, et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol 2015; 44(3): 827-36.
[http://dx.doi.org/10.1093/ije/dyv098 ] [PMID: 26050254]
[19]
WHO Collaborating Centre for Drug Statistics Methodology. https://www.whocc.no/atc_ddd_index/
[20]
Boyko EJ, Seelig AD, Ahroni JH. Limb- and Person-Level Risk Factors for Lower-Limb Amputation in the Prospective Seattle Diabetic Foot Study. Diabetes Care 2018; 41(4): 891-8.
[http://dx.doi.org/10.2337/dc17-2210 ] [PMID: 29439130]
[21]
Gurney JK, Stanley J, York S, Rosenbaum D, Sarfati D. Risk of lower limb amputation in a national prevalent cohort of patients with diabetes. Diabetologia 2018; 61(3): 626-35.
[http://dx.doi.org/10.1007/s00125-017-4488-8 ] [PMID: 29101423]
[22]
Jiang Y, Ran X, Jia L, et al. Epidemiology of type 2 diabetic foot problems and predictive factors for amputation in China. Int J Low Extrem Wounds 2015; 14(1): 19-27.
[http://dx.doi.org/10.1177/1534734614564867 ] [PMID: 25573978]
[23]
Monteiro-Soares M, Martins-Mendes D, Vaz-Carneiro A, Dinis-Ribeiro M. Lower-limb amputation following foot ulcers in patients with diabetes: classification systems, external validation and comparative analysis. Diabetes Metab Res Rev 2015; 31(5): 515-29.
[http://dx.doi.org/10.1002/dmrr.2634 ] [PMID: 25529456]
[24]
Dawwas GK, Smith SM, Park H. Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes. Diabetes Obes Metab 2019; 21(1): 28-36.
[http://dx.doi.org/10.1111/dom.13477 ] [PMID: 30039524]
[25]
Ueda P, Svanström H, Melbye M, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ 2018; 363: k4365.
[http://dx.doi.org/10.1136/bmj.k4365 ] [PMID: 30429124]
[26]
Suissa S. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018; 41(1): 6-10.
[http://dx.doi.org/10.2337/dc17-1223 ] [PMID: 29263192]
[27]
Li D, Yang JY, Wang T, Shen S, Tang H. Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: A Meta-analysis of Randomized Controlled Trials. Diabetes Metab 2018; 44(5): 410-4.
[http://dx.doi.org/10.1016/j.diabet.2018.02.001 ] [PMID: 29506779]
[28]
Jabbour S, Seufert J, Scheen A, Bailey CJ, Karup C, Langkilde AM. Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials. Diabetes Obes Metab 2018; 20(3): 620-8.
[http://dx.doi.org/10.1111/dom.13124 ] [PMID: 28950419]
[29]
Kohler S, Zeller C, Iliev H, Kaspers S. Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials. Adv Ther 2017; 34(7): 1707-26.
[http://dx.doi.org/10.1007/s12325-017-0573-0 ] [PMID: 28631216]
[30]
National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ng28
[31]
Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 1995; 48(12): 1503-10.
[http://dx.doi.org/10.1016/0895-4356(95)00048-8 ] [PMID: 8543964]
[32]
Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med 1991; 10(4): 577-81.
[http://dx.doi.org/10.1002/sim.4780100409 ] [PMID: 2057656]
[33]
Holman N, Young RJ, Jeffcoate WJ. Variation in the recorded incidence of amputation of the lower limb in England. Diabetologia 2012; 55(7): 1919-25.
[http://dx.doi.org/10.1007/s00125-012-2468-6 ] [PMID: 22398645]
[34]
Geiss LS, Li Y, Hora I, Albright A, Rolka D, Gregg EW. Resurgence of Diabetes-Related Nontraumatic Lower-Extremity Amputation in the Young and Middle-Aged Adult U.S. Population. Diabetes Care 2019; 42(1): 50-4.
[http://dx.doi.org/10.2337/dc18-1380 ] [PMID: 30409811]

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy